Meng H. Tan

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study

Philippe Ryvlin, Lina Nashef, Samden D. Lhatoo et al. · The Lancet Neurology · 2013 · 1.1K citations

Retrospective Study, Cardiopulmonary Resuscitation, Medicine +6

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg et al. · Diabetes Care · 2005 · 795 citations · Full text

Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

Erland Erdmann, B Charbonnel, Robert A. Wilcox et al. · Diabetes Care · 2007 · 280 citations · Full text

Increased Lipoprotein-Remnant Formation in Chronic Renal Failure

Paul J. Nestel, Noel Fidge, Meng H. Tan · New England Journal of Medicine · 1982 · 240 citations

Long-term Dialysis, Renal Pathology, Pathology +25